Today's commercially successful Dry Power Inhaler (DPI) products are not very efficient, typically depositing more drug in the mouth and throat of the patient, rather than delivering it to their lungs. This is largely because the science is complex and not well understood - combining transient fluid dynamics with particulate aerosols makes any modelling a challenge. Despite this, DPIs continue to increase in market share (over conventional pressurised metered dose inhalers - pMDIs). As our knowledge in this area increases, combined with ever-increasing computational power, it's likely that there will be substantial improvement to DPI performance over the next decade - opening up possibilities to deliver new drugs to the lung - beyond asthma and COPD.

1830-1900: refreshments and networking in the reception area
1900-2030: lecture in room LT6 followed by Q&A